Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2024-09-30 00:00:00 ET · period of report 2024-09-30 · accession 0001415889-24-024117 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-30 | 2024-09-30 | TVTX | Meckler Jeffrey A | Dir | S - Sale+OE | $14.06 | -40.0K | 81.0K | -33% | -$562.4K |
| D | 2024-09-30 | 2024-09-30 | TVTX | Meckler Jeffrey A | Dir | M - OptEx | $10.48 | +40.0K | 121.0K | +49% | +$419.2K |
| D | 2024-09-30 | 2024-09-30 | TVTX | Meckler Jeffrey A | Dir | M - OptEx | $0.00 | +40.0K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-30 | S | D | 40,000 | $14.06 | 81,000 | D | — | — | (F2) The weighted average sale price for the transaction reported was $14.0581, and the range of prices were between $13.782 and $14.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2024-09-30 | M | A | 40,000 | $10.48 | 121,000 | D | — | — | |
| 3 | Derivative | Stock option (right to buy) | 2024-09-30 | M | A | 40,000 | $0.00 | 0 | D | $10.48 · — to 2024-10-08 | 40,000 Common Stock | (F3) The stock option is fully vested and exercisable. |